Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Liver Diseases

Free Subscription 19.10.2026 1 Am J Pathol 3 Biochem Biophys Res Commun 8 BMC Gastroenterol 1 Cancer Res 8 Clin Res Hepatol Gastroenterol 3 Endoscopy 1 Eur J Pediatr 3 Eur Radiol 11 Hepatology 1 Indian J Gastroenterol 5 J Hepatol 1 Oncogene 2 PLoS One 1 Radiol Cardiothorac Imaging

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Pathol

1. CHEN X, Mazur A, Denning KL, Acquaah-Mensah GK, et al
   PEX16 absence-associated hepatocyte proliferation is mediated by FXR but suppressed by PPARalpha.
   Am J Pathol. 2026 Oct 13:S0002-9440(26)00289.
   PubMed         Abstract available
   
   

   
   Biochem Biophys Res Commun

2. ULKER M, Aydin Acar C
   OTUD7B associates with immune infiltration and pharmacogenomic profiles in hepatocellular carcinoma: An integrative multi-omics analysis.
   Biochem Biophys Res Commun. 2026;839:154712.
   PubMed         Abstract available
   
   
3. MIN JH, Hong Y, Lee M, Lee DE, et al
   Efonidipine inhibiting CYP4A attenuates palmitate-induced hepatocyte lipotoxicity.
   Biochem Biophys Res Commun. 2026;839:154723.
   PubMed         Abstract available
   
   
4. BI S, Zhang Y, Zhou J, Yao Y, et al
   Corrigendum to "miR-210 promotes hepatocellular carcinoma progression by modulating macrophage autophagy through PI3K/AKT/mTOR signaling" [Biochem. Biophys. Res. Commun. 662, (2023), 47e57].
   Biochem Biophys Res Commun. 2026 Oct 15:154727. doi: 10.1016/j.bbrc.2026.154727.
   PubMed        
   
   

   
   BMC Gastroenterol

5. ZHENG T, Yang H, Wang S, Shi X, et al
   Development and validation of an online dynamic nomogram for nonobese metabolic dysfunction-associated steatotic liver disease based on body composition analysis.
   BMC Gastroenterol. 2026;26:635.
   PubMed         Abstract available
   
   
6. CHEN Y, Shi L, Zhang X, Liu X, et al
   Real-world study of posaconazole tablets for the prophylaxis of invasive fungal disease in patients with end-stage liver disease.
   BMC Gastroenterol. 2026;26:646.
   PubMed         Abstract available
   
   
7. ZHU J, Liu Y, Lu S, Han Y, et al
   Risk factors and development of a predictive model for chronic kidney disease in patients with metabolic dysfunction-associated steatotic liver disease.
   BMC Gastroenterol. 2026;26:642.
   PubMed         Abstract available
   
   
8. LIU X, Yang S, Zhang C, Chen P, et al
   Accelerated biological aging and the risk of incident liver cancer: a prospective cohort study of the UK biobank.
   BMC Gastroenterol. 2026;26:650.
   PubMed         Abstract available
   
   
9. HAMOOD M, Al-Salehi MA, Hussein AF, Naji KM, et al
   Association between the PNPLA3 I148M (rs738409) polymorphism and risk of metabolic dysfunction-associated steatotic liver disease: a meta-analysis (2015-2025).
   BMC Gastroenterol. 2026;26:659.
   PubMed         Abstract available
   
   
10. XING Y, Wang J, Cheng H, Xiao M, et al
    Association of neutrophil-to-high-density lipoprotein ratio with all-cause mortality among individuals with non-alcoholic fatty liver disease: the NHANES database prospective cohort study.
    BMC Gastroenterol. 2026;26:653.
    PubMed         Abstract available
    
    
11. LIU R, Xiao Y, Wang Z, Yang Q, et al
    Cost-effectiveness analysis of durvalumab combined with tremelimumab versus sorafenib as first-line treatment for unresectable Hepatocellular carcinoma in China: a dual-model approach utilizing partitioned survival and markov models.
    BMC Gastroenterol. 2026;26:631.
    PubMed         Abstract available
    
    
12. HE X, Han J
    Log-transformed systemic inflammation response index improves prediction of 28-day ICU mortality in critically ill patients with cirrhosis and atrial fibrillation: development in MIMIC-IV and external validation in eICU-CRD.
    BMC Gastroenterol. 2026;26:655.
    PubMed         Abstract available
    
    

    
    Cancer Res

13. LI Q, Yuan Y, Liu N, Li L, et al
    ARID2 Loss Reprograms the Kynurenine-AhR Pathway to Restore Antitumor Immunity in CTNNB1-Mutant Hepatocellular Carcinoma.
    Cancer Res. 2026 Oct 14. doi: 10.1158/0008-5472.CAN-26-0860.
    PubMed         Abstract available
    
    

    
    Clin Res Hepatol Gastroenterol

14. BRUNET T, Giguet B, Masrour O, Rayer C, et al
    Alcohol-related cognitive impairment confounds covert hepatic encephalopathy screening by PHES and the simplified animal naming test.
    Clin Res Hepatol Gastroenterol. 2026;50:102884.
    PubMed         Abstract available
    
    
15. ALNOUNOU A, Nohomovich B, Alabbas M, Hickok K, et al
    Amebic liver abscess hospitalizations in the United States: A nationwide analysis of trends and severe morbidity, 2002-2023.
    Clin Res Hepatol Gastroenterol. 2026;50:102912.
    PubMed         Abstract available
    
    
16. KIM K, Ky V, Seng S, Nheb M, et al
    Benign Recurrent Intrahepatic Cholestasis in a resource-limited setting: The first reported case from Cambodia.
    Clin Res Hepatol Gastroenterol. 2026;50:102913.
    PubMed         Abstract available
    
    
17. SURESH KB, Bhatia R, Sajawal M, Sabet O, et al
    Gene-environment interaction between heavy alcohol use and PNPLA3 rs738409 in incident cirrhosis: Evidence from a diverse U.S. cohort.
    Clin Res Hepatol Gastroenterol. 2026;50:102909.
    PubMed         Abstract available
    
    
18. JIANG T, Cui XP, Yin YS, Xu DQ, et al
    Management of Portal Vein Thrombosis in Cirrhosis: Risks, Treatments, and Outcomes of a Retrospective Multicenter Study With Over 10 Years of Follow-Up.
    Clin Res Hepatol Gastroenterol. 2026 Aug 13:102902.
    PubMed         Abstract available
    
    
19. SAMAJDAR SS, Joshi SR, Bhaduri G, Saboo B, et al
    Efficacy and safety of empagliflozin in metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2026;50:102898.
    PubMed         Abstract available
    
    
20. QUAN AT
    From one-size-fits-all to on-demand: personalized crispr gene editing for rare genetic liver diseases.
    Clin Res Hepatol Gastroenterol. 2026;50:102892.
    PubMed         Abstract available
    
    
21. ELSABAAWY M, Ragab M, Al-Khalifa M, Gamil K, et al
    Sarcopenia in Decompensated Cirrhosis: A Comparative Analysis of Bioelectrical Impedance-Based Measures.
    Clin Res Hepatol Gastroenterol. 2026 Jul 28:102893.
    PubMed         Abstract available
    
    

    
    Endoscopy

22. GAINEY CS, Trieu JA, Hathorn KE, Baron TH, et al
    A novel single-catheter access device for endoscopic ultrasound-guided hepaticogastrostomy.
    Endoscopy. 2026 Oct 12. doi: 10.1055/a-2971-5161.
    PubMed        
    
    
23. HUANG J, Ruan X, Liu S, Zhuang K, et al
    Endoscopic ultrasound-guided selective inflow vessel devascularization and multi-point venous occlusion for gastric varices due to left-sided portal hypertension.
    Endoscopy. 2026 Oct 15. doi: 10.1055/a-2971-5252.
    PubMed        
    
    
24. SOGA K, Otani S, Takagi O, Yamaguchi M, et al
    Enteroscopic hemostasis for bleeding hepatopetal collaterals around a hepaticojejunostomy.
    Endoscopy. 2026 Oct 16. doi: 10.1055/a-2955-9801.
    PubMed        
    
    

    
    Eur J Pediatr

25. HEGARTY R, Zen Y, Sayer JA
    Hepatic manifestations of ciliopathies: genetic causes and clinical update.
    Eur J Pediatr. 2026;185:825.
    PubMed         Abstract available
    
    

    
    Eur Radiol

26. YOON JH, Lee ES, Kim YK, Lee CH, et al
    LI-RADS v2018 versus KLCA-NCC v2022: comparison of probability-based HCC categories.
    Eur Radiol. 2026;36:8451-8464.
    PubMed         Abstract available
    
    
27. SCHMIDT VF, Linden P, Dietrich O, Deniz S, et al
    MR-guided microwave ablation of liver tumors: outcomes in local tumor control and determinants of treatment success.
    Eur Radiol. 2026;36:8052-8061.
    PubMed         Abstract available
    
    
28. BIJLSTRA OD, van Mossel S, Boekestijn B, Burgmans MC, et al
    Improved detection of local tumor progression after ablation or resection of colorectal liver metastases using [(18)F]FDG-PET/contrast-enhanced CT versus contrast-enhanced CT alone: results from a Dutch prospective cohort.
    Eur Radiol. 2026;36:8197-8205.
    PubMed         Abstract available
    
    

    
    Hepatology

29. HU ZQ, Zhou SL, Li J, Zhou ZJ, et al
    Erratum: Circular RNA sequencing identifies CircASAP1 as a key regulator in hepatocellular carcinoma metastasis.
    Hepatology. 2026 Oct 13. doi: 10.1097/HEP.0000000000001845.
    PubMed        
    
    
30. WANG L, Li H, Yang L, Li J, et al
    Upholding telomeres prevents hepatic stellate cell transdifferentiation and liver fibrogenesis.
    Hepatology. 2026 Oct 14. doi: 10.1097/HEP.0000000000001889.
    PubMed         Abstract available
    
    
31. MAHMUD N, Schechter MS, Zhang S, Mezzacappa C, et al
    Intravenous albumin after outpatient paracentesis reduces the risk of AKI hospitalization: A national cohort study.
    Hepatology. 2026;84:1415-1425.
    PubMed         Abstract available
    
    
32. CHENG Y, Li ZD, Guan ZH, Wang L, et al
    Liver transcriptome sequencing contributes to the molecular diagnosis of genetic liver diseases.
    Hepatology. 2026;84:1270-1285.
    PubMed         Abstract available
    
    
33. JIN ZC, Wei J, Xiao YD, Si A, et al
    Decoding tumor heterogeneity with imaging biomarkers predicts response to TACE plus immunotherapy and targeted therapy in HCC (CHANCE2204).
    Hepatology. 2026;84:1303-1316.
    PubMed         Abstract available
    
    
34. BOUGUERRA R, El Hajji S, Wassmer CH, Bakaric A, et al
    Hepatectomy alters adjuvant anti-PD-1 action in a mouse model of HCC but does not compromise neoadjuvant efficacy.
    Hepatology. 2026;84:1381-1395.
    PubMed         Abstract available
    
    
35. ADAMS LA, Thiele M, Tsochatzis EA
    Detecting at-risk steatotic liver disease and liver fibrosis in the community.
    Hepatology. 2026;84:1548-1566.
    PubMed         Abstract available
    
    
36. QIN S, Bo X, Liu H, Zhang Z, et al
    Cell therapies and liver organogenesis technologies: Promising strategies for end-stage liver disease.
    Hepatology. 2026;84:1567-1586.
    PubMed         Abstract available
    
    
37. ERICKSON H
    Turning down the ammonia dial: Phase 2a evidence for YAQ007 in cirrhosis.
    Hepatology. 2026;84:1251-1252.
    PubMed        
    
    
38. UDOMPAP P
    A gentler squeeze: A first signal from OCE-205, a selective V1a mixed agonist-antagonist for hepatorenal syndrome-acute kidney injury.
    Hepatology. 2026;84:1247-1248.
    PubMed        
    
    
39. SAMALA N, Gonzalez-Gonzalez J, Jenders RA, Sarkar M, et al
    Saroglitazar improves hepatic steatosis and liver enzymes in women with polycystic ovary syndrome and MASLD: A multicenter, double-blind, placebo-controlled study.
    Hepatology. 2026 Oct 15. doi: 10.1097/HEP.0000000000001862.
    PubMed         Abstract available
    
    

    
    Indian J Gastroenterol

40. MUNIR AB, Imran H, Faraz N
    Comment on "Albumin-bilirubin grade and sarcopenia as predictors of prognosis in patients with unresectable intermediate and advanced-stage hepatocellular carcinoma".
    Indian J Gastroenterol. 2026 Oct 9. doi: 10.1007/s12664-026-02093.
    PubMed        
    
    

    
    J Hepatol

41. BASHIR DA, Thadani S, Nack T, Gebara N, et al
    Abnormal left ventricular mass as a prognostic marker for outcomes in infants and children with cirrhosis.
    J Hepatol. 2026 Oct 12:S0168-8278(26)02924-7. doi: 10.1016/j.jhep.2026.
    PubMed         Abstract available
    
    
42. XIAO P, Zai Q, Ma N, Zhang J, et al
    Interleukin-19 ameliorates drug-induced liver injury by limiting proinflammatory macrophage infiltration via SUMOylation of C/EBPbeta.
    J Hepatol. 2026;85:868-881.
    PubMed         Abstract available
    
    
43. WEI H, Heo S, Yang Y, Li M, et al
    MRI-based prediction of very early recurrence within 1 year after resection of HCC: An international cohort study.
    J Hepatol. 2026;85:912-929.
    PubMed         Abstract available
    
    
44. PENG N, Song SJ, Wang MY, Lai JC, et al
    HbA1c trajectories and the risk of liver-related events in patients with type 2 diabetes mellitus.
    J Hepatol. 2026;85:843-854.
    PubMed         Abstract available
    
    
45. BURT AD, Behling C, Gouw ASH, Hytiroglou P, et al
    Fibrosis regression in chronic liver disease: The pathologist's view.
    J Hepatol. 2026;85:1033-1039.
    PubMed         Abstract available
    
    

    
    Oncogene

46. XU Y, Li JJ, Zhou LE, Liu HH, et al
    Matrix stiffness drives HCC invasion and metastasis via interfering with TRIM21-mediated SCD1 ubiquitination.
    Oncogene. 2026;45:3230-3243.
    PubMed         Abstract available
    
    

    
    PLoS One

47. ELIAS TP, Shewaye AB, Berhane KA, Mohammed A, et al
    Histopathologic spectrum of focal liver lesions diagnosed by ultrasound-guided percutaneous liver biopsy and predictors of hepatocellular carcinoma: A single-center experience from Sub-Saharan Africa.
    PLoS One. 2026;21:e0357210.
    PubMed         Abstract available
    
    
48. PAN K, Chen L, Zheng Y
    integrating single-cell transcriptomics and chromatin accessibility profiling to decipher the molecular landscape of Hepatocellular carcinoma.
    PLoS One. 2026;21:e0359329.
    PubMed         Abstract available
    
    

    
    Radiol Cardiothorac Imaging

49. KARAHACIOGLU D, Cural Kula G, Kula S, Veznikli M, et al
    Opportunistic Detection of Hepatic Steatosis Using Postcontrast Liver Attenuation at Coronary CT Angiography.
    Radiol Cardiothorac Imaging. 2026;8:e260148.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum